INAB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers...

Stats
Šios dienos apimtis	195 307
Vidutinė apimtis	343 516
Rinkos kapitalizacija	44.15M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.170 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.020
ATR14	$0.00900 (0.90%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Epperly Corinne	Buy	12 500	Stock Option (right to buy)
2024-02-07	Ho William Tai-wei	Buy	502 000	Employee Stock Option (right to buy)
2024-02-07	Goswami Trishna	Buy	176 000	Employee Stock Option (right to buy)
2024-02-07	Rochlin Kate	Buy	186 000	Employee Stock Option (right to buy)
2024-02-07	Lamb Lawrence	Buy	169 000	Employee Stock Option (right to buy)

INSIDER POWER
24.71
Last 98 transactions
Buy: 9 531 383 \| Sell: 5 834 681

Tūris Koreliacija

Ilgas: -0.12 (neutral)

Trumpas: -0.74 (moderate negative)

Signal:(33.579) Neutral

IN8bio, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PCVX	0.832
DTSS	0.822
IMPL	0.82
SLM	0.816
AFYA	0.815
JAZZ	0.814
AVIR	0.811
PDSB	0.811
LIVN	0.806
GOEV	0.805

10 Labiausiai neigiamai susiję koreliacijos
PAE	-0.843
RAVN	-0.832
NEO	-0.828
ZGNX	-0.813
SERA	-0.813
PEGA	-0.81
ACVA	-0.81
EBAC	-0.809
ICON	-0.808
TA	-0.807

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

IN8bio, Inc. Koreliacija - Valiuta/Žaliavos

-0.38
( neutral )

-0.37
( neutral )

0.00
( neutral )

0.18
( neutral )

0.59
( weak )

IN8bio, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2023
Pajamos:	$0
Bruto pelnas:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.10M (0.00 %)
EPS:	$-1.310

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.095

Financial Reports:

No articles found.

IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.